Coralie Bélanger

University of Toronto — Canada

Medicine · Health Sciences

23h-index3.1kcitations84works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(25), Chronic Lymphocytic Leukemia Research(21), Nanoparticle-Based Drug Delivery(20), RNA Interference and Gene Delivery(20), Hematopoietic Stem Cell Transplantation(17)

Publications84 total

Final results of a first-in-human Phase I study of INA03, a novel CD71/TfR1-targeted antibody-drug conjugate, in patients with relapsed or refractory acute leukemia.
Blood·2025Open Access
Flow virometry: recent advancements, best practices, and future frontiers
Journal of Virology·2025· 6 citedOpen Access
Supplementary Figure S1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S7 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S6 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 1 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S5 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S4 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Data from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Figure S2 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
Supplementary Table 3 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Olivier Hermine(15), Bruno Varet(13), Nicole Brousse(7), François Lefrère(7), François Dreyfus(5), Bertrand Arnulf(5), Gabriel Étienne(5), Agnès Buzyn(5), Maud Janvier(4), Josy Reiffers(4), Pauline Brice(4), François‐Xavier Mahon(4), Françoise Valensi(4), Éliane Gluckman(4), André Goy(4), Marina Cavazzana(4), Pierre Launay(4), Jean‐Paul Fermand(3), Philippe Ravaud(3), Sylvie Chevret(3)